STOCK TITAN

FibroGen, Inc. - $FGEN STOCK NEWS

Welcome to our dedicated page for FibroGen news (Ticker: $FGEN), a resource for investors and traders seeking the latest updates and insights on FibroGen stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect FibroGen's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of FibroGen's position in the market.

Rhea-AI Summary

FibroGen announced positive interim data from a Phase 1b study of FG-3246 (FOR46) in combination with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) patients. Presented at the 2024 ASCO Annual Meeting, the study revealed a median radiographic progression-free survival (rPFS) of 10.2 months in biomarker-unselected patients. FG-3246, an anti-CD46 antibody-drug conjugate, showed an acceptable safety profile with adverse events similar to other MMAE-based therapies. The recommended Phase 2 dose for FG-3246 is set at 2.1 mg/kg every three weeks alongside enzalutamide at 160 mg daily.

The trial involved 17 patients, most of whom had received at least two prior androgen receptor signaling inhibitors. The study explored dose escalation with and without granulocyte colony-stimulating factor (G-CSF) support. The primary endpoint was to determine the maximally tolerated dose (MTD) of FG-3246, established at 2.1 mg/kg ABW with primary G-CSF prophylaxis in combination with enzalutamide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
-
Rhea-AI Summary

FibroGen, Inc. (NASDAQ: FGEN) will participate in upcoming investor conferences such as Bank of America Health Care Conference and H.C. Wainwright Bioconnect Investor Conference. The company's management will engage in 1x1 investor meetings and a Fireside Chat on specific dates in May 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.1%
Tags
conferences
-
Rhea-AI Summary

FibroGen, Inc. (NASDAQ: FGEN) reported strong financial results for Q1 2024, showing a 55% year-over-year net revenue growth driven by roxadustat sales in China and one-time revenue from the termination of the US/RoW AstraZeneca agreement. The company has a healthy cash balance of $214.7 million, ensuring financial stability till 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.1%
Tags
Rhea-AI Summary

FibroGen, Inc. (NASDAQ: FGEN) will report its first quarter 2024 financial results on May 6 after the market close. The company will hold a conference call to discuss its financial and corporate performance.

Interested parties can access the live webcast on the company's website. Dial-in details are available for phone participants. A webcast replay will be available for a time.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.81%
Tags
conferences earnings
-
Rhea-AI Summary
FibroGen, Inc. announces the selection of clinical data from the dose escalation portion of the Phase 1b/2 study of FG-3246 in combination with enzalutamide for a poster presentation at the 2024 American Society of Clinical Oncology Annual Meeting. The presentation focuses on a novel antibody-drug conjugate targeting a tumor-specific epitope of CD46 in patients with metastatic castration resistant prostate cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.63%
Tags
-
Rhea-AI Summary
FibroGen, Inc. (NASDAQ: FGEN) announces positive topline data from the Phase 1 study of FG-3246, an anti-CD46 antibody drug conjugate, in metastatic castration-resistant prostate cancer patients. Key findings include a median radiographic progression free survival of 8.7 months, PSA50 response in 36% of patients, and a radiographic objective response rate of 20%. The company plans to initiate Phase 2 trials in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.94%
Tags
Rhea-AI Summary
FibroGen, Inc. (FGEN) CEO to present at Needham Healthcare Conference, offering virtual one-on-one meetings with investors. Event details, webcast link, and replay information provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.58%
Tags
conferences
-
Rhea-AI Summary
FibroGen, Inc. appoints Dr. Deyaa Adib, an experienced oncology leader, as Senior Vice President & Chief Medical Officer. His extensive background in oncology drug development will drive the company's oncology pipeline forward, focusing on bringing novel cancer therapies to patients in need.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
management
-
Rhea-AI Summary
FibroGen, Inc. (FGEN) reports positive financial results for FY 2023, with a 5% increase in total net revenue. The company anticipates topline data from pivotal pancreatic cancer trials in 2Q 2024 and additional data from a Phase 1 study in 1Q 2024. FibroGen also regains rights to roxadustat from AstraZeneca in certain territories, showing robust volume growth in China. The company's cost reduction plan has been successful, with a cash runway into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.59%
Tags
Rhea-AI Summary
FibroGen terminates U.S./RoW roxadustat collaboration agreement with AstraZeneca, retains rights outside China. FibroGen to explore licensing opportunities for roxadustat. Roxadustat remains a leader in China for CKD anemia treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.59%
Tags
none
FibroGen, Inc.

Nasdaq:FGEN

FGEN Rankings

FGEN Stock Data

129.32M
82.99M
6.37%
71.45%
5.26%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SAN FRANCISCO

About FGEN

fibrogen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. the company has built upon its extensive research experience in fibrosis and hypoxia-inducible factor (hif) biology to generate clinical programs targeting multiple therapeutic areas. fibrogen's most advanced product candidate, roxadustat (fg-4592), is an oral small molecule inhibitor of hif prolyl hydroxylases (hif-phs), in phase 3 clinical development for the treatment of anemia in chronic kidney disease (ckd). our second product candidate, fg-3019, is a monoclonal antibody in phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (ipf), pancreatic cancer and liver fibrosis. for more information please visit: www.fibrogen.com.